The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries

Journal of Infectious Diseases

Volumn 196, Issue 10, 2007, Pages 1447-1454

  Kjær, Susanne Krüger ^a   Tran, Trung Nam ^b,c   Sparen, Par ^c   Tryggvadottir, Laufey ^d   Munk, Christian ^a   Dasbach, Erik ^b   Liaw, Kai Li ^b   Nygård, Jan ^e   Nygård, Mari ^e  

^a Rigshospitalet   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ICELANDIC CANCER SOCIETY   (Iceland)

^e CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ASSESSMENT; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SELF REPORT; SEXUAL INTERCOURSE; SEXUALITY; WART VIRUS; ADOLESCENT; AGE; CLINICAL TRIAL; COST OF ILLNESS; CROSS-SECTIONAL STUDY; ICELAND; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMA VIRUS; SCANDINAVIA; SEXUAL BEHAVIOR; VIRUS INFECTION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; CONDYLOMATA ACUMINATA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ICELAND; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUESTIONNAIRES; SCANDINAVIA; SEXUAL BEHAVIOR;

EID: 38449105799     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522863     Document Type: Article

References (34)

1. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998; 9:571-8.
2. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996; 7:197-200.
3. Friis S, Kjær SK, Frisch M, Mellemkjær L, Olsen JH. Cervical intraepithelial neoplasia, anogenital cancer, and other cancer types in women after hospitalization for condylomata acuminata. J Infect Dis 1997; 175:743-8.
4. Kjær SK, Dahl C, Engholm G, Bock JE, Lynge E, Jensen OM. Case-control study of risk factors for cervical neoplasia in Denmark. II. Role of sexual activity, reproductive factors, and venereal infections. Cancer Causes Control 1992; 3:339-48.
5. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36:1397-403.
6. Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006; 22:663-70.
7. Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984; 120:469-75.
8. Kjær SK, Lynge E. Incidence, prevalence and time trends of genital HPV infection determined by clinical examination and cytology. IARC Sci Publ 1989 ; 94:113.
9. Gall SA. Female genital warts: global trends and treatments. Infect Dis Obstet Gynecol 2001; 9:149-54.
10. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-63.
11. Burkett BJ, Peterson CM, Birch LM, et al. The relationship between contraceptives, sexual practices, and cervical human papillomavirus infection among a college population. J Clin Epidemiol 1992; 45:1295-302.
12. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-52.
13. Munk C, Svare EI, Poll P, Bock JE, Kjær SK. History of genital warts in 10,838 women 20 to 29 years of age from the general population: risk factors and association with Papanicolaou smear history. Sex Transm Dis 1997; 24:567-72.
14. Khan A, Hussain R, Schofield M. Correlates of sexually transmitted infections in young Australian women. Int J STD AIDS 2005; 16:482-7.
15. Sattler C, for the FUTURE I Investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL) [abstract LB2-25]. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2005.
16. Grulich AE, de Visser RO, Smith AMA, Rissel CE, Richters J. Sex in Australia: sexually transmissible infection and blood-borne virus history in a representative sample of adults. Aust N Z J Public Health 2003; 27:234-41.
17. Kjær SK, Dahl C, Bock JE, et al. [Sexual habits of women aged 20-39 years: a comparison of 3 population-based studies from Nykobing Falster, Copenhagen and Nuuk/Godthab.] Ugeskr Laeger 1990; 152:2727-31.
18. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 2004; 80:255-63.
19. Boelskifte J, Saval PM, Rasmussen KL. [Sexual activity and contraception habits among adolescents over the last 14 years: an investigation among 9th grade pupils in the municipality of Viborg.] Ugeskr Laeger 2002; 164:3207-11.
20. Kangas I, Andersen B, McGarrigle CA, Ostergaard L, Alvarez FB. A comparison of sexual behaviour and attitudes of healthy adolescents in a Danish high school in 1982, 1996, and 2001. Popul Health Metr 2004; 2:5.
21. Bender S, Geirsson RT, Kosunen E. Trends in teenage fertility, abortion, and pregnancy rates in Iceland compared with other Nordic countries, 1976-99. Acta Obstet Gynecol Scand 2003; 82:38-47.
22. Sigurdsson K, Sigvaldason H. Longitudinal trends in cervical cytological lesions and the effect of risk factors: a 30-year overview. Acta Obstet Gynecol Scand 2006; 85:350-8.
23. Dillner J. Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 2000; 19:7-23.
24. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 2003; 84(Pt 8):2105-9.
25. Habel LA, Van Den Eeden SK, Sherman KJ, McKnight B, Stergachis A, Daling JR. Risk factors for incident and recurrent condylomata acuminata among women: a population-based study. Sex Transm Dis 1998; 25:285-92.
26. Ross JD. Is oral contraceptive associated with genital warts? Genitourin Med 1996; 72:330-3.
27. Wiley DJ, Grosser S, Qi K, et al. Validity of self-reporting of episodes of external genital warts. Clin Infect Dis 2002; 35:39-45.
28. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358:1835-42.
29. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
30. Brown DR, Fife KH, Wheeler CM, et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 2004; 22:2936-42.
31. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
32. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
33. Lehtinen M, Paavonen J. Vaccination against human papillomaviruses shows great promise. Lancet 2004; 364:1731-2.
34. Markowitz L, Dunne E, Gilsdorf J. Development of recommendations for HPV vaccine use in the United States. In: Program and abstracts of the Papillomavirus 22nd International Conference and Clinical Workshop 2005 (Vancouver). 2005.